title: A new strategy to prevent chemotherapy and radiotherapy-induced alopecia using topically applied vasoconstrictor.
abstract: In a new strategy, we sought to determine whether topically applied vasoconstrictor, with its accompanying transient skin hypoxia and exclusion of systemic drug, would prevent or suppress radiotherapy or chemotherapy-induced alopecia. Topical vasoconstrictor was applied to 1-cm(2) skin patches on the backs of 10-day-old rats and minutes later they received either 7.1 gray (Gy) whole-body radiation or systemic N-nitroso-N-methylurea (MNU) or Cytoxan. The degree of alopecia was scored 10 days later by visual assessment (% coat retention) and hair follicle histologic analysis. Topical application of epinephrine or norepinephrine in an alcohol:water delivery vehicle induced clear skin blanch, and in a dose-dependent manner, topical epinephrine or norepinephrine (20-1,000 mM) applied before 7.1 Gy irradiation conferred 95% of coat retention in the treated skin patches versus 0% coat retention in vehicle controls, or in skin outside the treated patches. By histology, small numbers of dystrophic hair follicles were observed in hairless skin versus the normal density of anagen follicles in the immediately adjacent, drug-protected skin patches at day 20; protected coats were retained into adulthood. Topical epinephrine or norepinephrine before systemic MNU (30 ug/gm body weight) conferred up to 95% of coat retention in treated skin patches versus 0% coat retention elsewhere. Epinephrine-conferred % coat retention dropped to 16% in rats that received systemic Cytoxan, a drug whose plasma half-life is at least 8- to 10-fold longer than MNU. A general strategy is discussed for the use of topical epinephrine or norepinephrine in the clinic to provide an inexpensive and convenient strategy to prevent cancer therapy-induced alopecia.
authors.affiliation: McArdle Laboratory for Cancer Research, University of Wisconsin Carbone Cancer Center, Madison, WI; ProCertus BioPharm, Inc., Madison, WI.
authors.forename: Cheryl M
authors.initials: CM
authors.lastname: Soref
authors.forename: William E
authors.initials: WE
authors.lastname: Fahl
mesh_terms: D000287:Administration, Topical; D000505:Alopecia / Q000139:chemically induced / Q000517:prevention & control*; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D003520:Cyclophosphamide / Q000009:adverse effects*; D004837:Epinephrine / Q000008:administration & dosage*; D005260:Female; D009638:Norepinephrine / Q000008:administration & dosage*; D011833:Radiation Injuries, Experimental / Q000517:prevention & control*; D011836:Radiation Tolerance / Q000187:drug effects; D011837:Radiation-Protective Agents / Q000008:administration & dosage; D017207:Rats, Sprague-Dawley; D014662:Vasoconstrictor Agents / Q000008:administration & dosage*
chemical_list: D000970:Antineoplastic Agents; D011837:Radiation-Protective Agents; D014662:Vasoconstrictor Agents; D003520:Cyclophosphamide; D009638:Norepinephrine; D004837:Epinephrine
keywords: alpha adrenergic vasoconstrictor; epinephrine; norepinephrine; topical formulation